MB, MD, FRCPI, FERS, FRCPC, FACP, FACCP
Professor, Division of Respiratory Medicine, The University of British Columbia and Vancouver General Hospital
Co-Director, UBC Institute for Heart and Lung Health
Director, Centre for Heart and Lung Health
Senior Scientist, Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute
Dr. FitzGerald’s clinical and research interests include asthma, chronic obstructive lung disease, tuberculosis, and health outcomes. His current research focuses on health literacy and ethnicity in the management of asthma and Chronic Obstructive Pulmonary Disease (COPD) as well as the economic evaluation of asthma and its cost effective treatment.
Dr. FitzGerald is past Chair of both the Global Initiative for Asthma (GINA) Science Committee and Chair of the GINA Executive. He continues as a current member of both. He is past President of the Canadian Thoracic Society. He has published over 500 peer reviewed papers and editorials in high impact journals including: the New England Journal of Medicine, British Medical Journal, The Lancet, Annals of Internal Medicine and the Journal of the American Medical Association.
FitzGerald, JM, Sadatsafavi M. Triple therapy in a single inhaler: a new option for uncontrolled asthma. Lancet. 2019 Sep 30. pii: S0140-6736(19)32216.
Halpin DMG, Meltzer EO, Pisternick-Ruf W, Moroni-Zentgraf P, Engel M, Zaremba-Pechmann L, Casale T, FitzGerald JM. Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV1. Respir Res. 2019 Jul 18;20(1):159. doi: 10.1186/s12931-019-1119-6.
Reddel HK, FitzGerald JM, Bateman ED, Bacharier LB, Becker A, Brusselle G, Buhl R, Cruz AA, Fleming L, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Pedersen SE, Sheikh A, Yorgancioglu A, Boulet LP. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019 Jun 27;53(6). pii: 1901046. doi: 10.1183/13993003.01046-2019.
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496.
Busse WW, Bleecker ER, FitzGerald JM, et al Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019: S2213-2600(18)30406-5.
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018 Jan;6(1):51-64.
Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1877-1887
O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018 May 17;378(20):1865-1876
van der Heide I, Poureslami I, Mitic W, Shum J, Rootman I, FitzGerald JM. Health literacy in chronic disease management: a matter of interaction. J Clin Epidemiol. 2018 May 21. pii: S0895-4356(17)30943-5
FitzGerald JM, Lemiere C, Lougheed, D et al Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Can Journal of Resp, Critical Care and Sleep Medicine 2017;1:4: 199-221
Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, Mansfield L, Barker P, Wu Y, Jison M, Goldman M; BISE Study Investigators. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017 Jul;5(7):568-576. doi: 10.1016/S2213-2600(17)30190-X. Epub 2017 May 22. PMID: 28545978 [PubMed - in process]
FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies Lancet Respir Med. 2017 Sep 8. pii: S2213-2600(17)30344-2. doi: 10.1016/S2213-2600(17)30344-2. PMID: 28919200
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Sep 2. pii: S0140-6736(16)31324-1. doi: 10.1016/S0140-6736(16)31324-1. PMID: 27609408
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Sep 5. pii: S0140-6736(16)31322-8. doi: 10.1016/S0140-6736(16)31322-8. PMID: 27609406
All CIC publications featuring Dr. FitzGerald as a co-author are listed below.
| Author(s) | Year | Title | Journal |
|---|---|---|---|
| Gauvreau GM, FitzGerald JM, Boulet L-P, Watson R, Hui L, Villeneuve H, Scime T, Schlatman A, Obminski C, Kum J, Boehme S, Ly TW, Bacon K, O'Byrne PM | 2018 | The Effects of a CCR3 Inhibitor, AXP1275, on Allergen-Induced Airway Responses in Adults with Mild-to Moderate Atopic Asthma | Clinical & Experimental Allergy |
| Singh A, Shannon CP, Kim YW, Yang CX, Balshaw R, Cohen Freue GV, Gauvreau GM, FitzGerald JM, Boulet L-P, O'Byrne PM, Tebbutt SJ | 2018 | Novel blood-based transcriptional biomarker panels predict the late phase asthmatic response | American Journal of Respiratory and Critical Care Medicine |
| Tavakoli H, FitzGerald JM, Chen W, Lynd L, Kendzerska T, Aaron S, Gershon A, Marra C, Sadatsafavi M; Canadian Respiratory Research Network. | 2017 | Ten-year trends in direct costs of asthma: a population-based study | Allergy |
| O’Byrne P. M. FitzGerald JM, Zhong, N et al. | 2017 | The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given as needed in mild asthma: study protocols for two randomised controlled trials | Trials |
| Gauvreau GM, Boulet LP, FitzGerald JM, Cockcroft DW, Davis BE, Leigh R, Tanaka M, Fourre JA, Tanaka M, Nabata T, O'Byrne PM | 2016 |
Allergy |
|
| Sadatsafavi M, Chen W, Tavakoli H, Rolf JD, Rousseau R, FitzGerald JM | 2016 | Economic Burden of Asthma Study Group. Saving in medical costs by achieving guideline-based asthma symptom control: a population-based study | Allergy |
| Silkoff PE, Laviolette M, Singh D, FitzGerald JM, Kelsen S, Backer V, Porsbjerg C, Girodet PO, Berger P, Kline JN, Khatri S, Chanez P, Susulic VS, Barnathan ES, Baribaud F, Loza MJ; ADEPT Investigators. | 2016 | Longitudinal stability of asthma characteristics and biomarkers from the Airways Disease Endotyping for Personalized Therapeutics (ADEPT) study | Respiratory Research |
| FitzGerald JM, Sadatsafavi M. | 2016 | Less chaos in the prognosis of asthma-chronic obstructive lung disease overlap | The Lancet Respiratory Medicine |
| Ehteshami-Afshar S, FitzGerald JM, Carlsten C, Tavakoli H, Rousseau R, Tan WC, Rolf JD, Sadatsafavi M. | 2016 | The impact of comorbidities on productivity loss in asthma patients | Respiratory Research |
| Wong A, Tavakoli H, Sadatsafavi M, Carlsten C, FitzGerald JM. | 2016 | Asthma control and productivity loss in those with work-related asthma: a population-based study | Journal of Asthma |
| Sadatsafavi M, Tavakoli H, Lynd L, FitzGerald JM | 2016 | Has asthma medication use caught up with the evidence? | CHEST |
| Poureslami I, Shum J, Nimmon L, FitzGerald JM. | 2016 | Culturally Specific Evaluation of Inhaler Techniques in Asthma | Respiratory Care |
| Chen W, Lynd LD, FitzGerald JM, Marra CA, Balshaw R, To T, Tavakoli H, Sadatsafavi M. Canadian Respiratory Research Network. | 2016 | Excess medical costs in patients with asthma and the role of comorbidity | European Respiratory Journal |
| Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, Goldman M; SIROCCO study investigators. | 2016 | The Lancet | |
| FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators | 2016 | Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial | The Lancet |
| Gauvreau GM, Harris JM, Boulet LP, Sheerens H, FitzGerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y, Dahlén B, Wang Y, Maciuca R, Mayers I, Liao XC, Wu LC, Matthews JG, O'Byrne PM. | 2014 |
Science Translational Medicine |
|
| Gauvreau GM, O'Byrne PM, Boulet L-P, Wang Y, Cockcroft DW, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C, Gorski KS, Smith L, Bautista E, Comeau MR, Leigh R, Parnes JR. | 2014 |
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses |
The New England Journal of Medicine |
| Gauvreau GM, Boulet L-P, Cockcroft DW, FitzGerald JM, Mayers I, Carlsten C, Laviolette M, Killian KJ, Davis BE, Larché M , Kipling C , Dua B , Mosesova S , Putnam W , Zheng Y, Scheerens H, McClintock D , Matthews J, O'Byrne PM | 2014 |
OX40L blockade on allergen-induced airway responses in subjects with mild asthma |
Clinical Experimental Allergy |
| Singh A, Yamamoto M, Kam SHY, Ruan J, Gauvreau GM, O'Byrne PM, FitzGerald JM, Schellenberg R, Boulet L-P, Wojewodka G, Kanagaratham C, De Sanctis J, Radzioch D, Tebbutt SJ. | 2013 |
PLOS ONE |
|
| Kam SHY, Singh A, He J-Q, Ruan J, Gauvreau GM, O'Byrne PM, FitzGerald JM, Tebbutt SJ. | 2012 |
Journal of Asthma |
|
| Singh A, Cohen Freue GV, Oosthuizen JL, Kam SHY, Ruan J, Takhar M, Gauvreau GM, O'Byrne PM, FitzGerald JM, Boulet L-P, Borchers CH, Tebbutt SJ. | 2012 | Plasma proteomics can discriminate isolated early from dual responses in asthmatic individuals undergoing an allergen inhalation challenge |
Proteomics ? Clinical Applications |
| Yamamoto M, Singh A, Ruan J, Gauvreau GM, O'Byrne PM, Carlsten C, FitzGerald JM, Boulet L-P, Tebbutt SJ. | 2012 |
BMC Genomics |
|
| Lougheed MD, Lemière C, Ducharme FM, Lickai C, Dell SD, Rowe BH, Fitzgerald M, Leigh R, Watson W, Boulet L-P. | 2012 | Canadian Thoracic Society 2012 Guideline Update: Diagnosis and Management of Asthma in Preschoolers, Children and Adults: Executive Summary |
Canadian Respiratory Journal |
| Fitzgerald M. | 2012 |
Evidence-Based Medicine for Primary Care and Internal Medicine |
|
| Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. | 2011 |
The effects of IL-13 blockade on allergen-induced airway responses in mild atopic asthma |
American Journal of Respiratory and Critical Care Medicine |
| Gaurvreau GM, Boulet LP, Cockcroft DW, FitzGerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Zhou S, Raible D, O'Byrne PM. | 2010 |
Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma |
American Journal of Respiratory and Critical Care Medicine |
| O'Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, FitzGerald JM, Watson RM, Milot J, Davis B, O?Connor M, Hart L, Korducki L, Hamilton J. | 2009 | Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in mild asthmatics |
Journal of Allergy and Clinical Immunology |